Endocyte has a pipeline of folate-targeted small molecule drug conjugates in various stages of clinical and preclinical development for the treatment of FR positive cancers and inflammatory diseases.About Lung Cancer Lung cancer is the leading cause of cancer deaths in the industrialized world. More than 200,000 new cases of lung cancer are diagnosed each year in the United States, and more than 160,000 deaths occur annually from the disease, according to the American Cancer Society. The disease is frequently not diagnosed until it has already developed to advanced stages, resulting in a five-year survival rate of approximately 15 percent. Approximately 85 percent of patients diagnosed with lung cancer are identified with non-small cell lung cancer, and of these patients 40 to 50 percent have adenocarcinomas and 30 to 35 percent have squamous cell carcinoma. About Etarfolatide (EC20) Etarfolatide is a folate-targeted companion diagnostic imaging agent that is being developed as a non-invasive method to identify tumors that over-express folate receptors. These tumors are the molecular target of Endocyte's folate-targeted therapeutic compounds such as vintafolide. Folic acid is used with etarfolatide for the enhancement of image quality. To date, etarfolatide and folic acid have been administered to over 590 patients. About Endocyte Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.